Literature DB >> 22890594

Prognostic factors and outcomes of patients with myxofibrosarcoma.

G Petur Nielsen1, John T Mullen2, Nicole J Look Hong2, Francis J Hornicek3, Kevin A Raskin3, Sam S Yoon2, Jackie Szymonifka4, Beow Yeap4, Yen-Lin Chen5, Thomas F DeLaney5.   

Abstract

BACKGROUND: Myxofibrosarcomas (MFS) are a historically heterogeneous group of tumors that exhibit a propensity for local recurrence. The objectives of this study were to analyze the prognostic factors and outcomes of patients with MFS treated at a single institution.
METHODS: We retrospectively reviewed the records of 69 consecutive patients with pathologically confirmed MFS of the extremities or superficial trunk who underwent surgery from August 1995 to November 2010. Clinicopathologic features, treatments, and patient outcomes were reviewed.
RESULTS: Sixty-nine patients were identified, of whom 38 were men (55%). The median age was 62 years. Sixty-four patients (93%) presented with primary tumors, and 5 patients (7%) presented with locally recurrent tumors. Median tumor size was 6.0 cm, and 44 patients (64%) had grade 3 tumors (FNCLCC [Fédération Nationale des Centres de Lutte Contre le Cancer] classification). Margins were microscopically positive in 14 patients (20%) and negative in 55 patients (80%), including close margins (<1 mm) in 14 patients (20%). Fifty-three patients (77%) received radiotherapy. At a median follow-up of 41 months, there were 11 local (16%) and 11 distant (16%) recurrences. The local and distant 5-year recurrence-free survival rates were 72% and 82%, and the 5-year overall survival was 61%. Increased age (scaled by 0.1; hazard ratio [HR] 1.80, P=0.002) and tumor size (HR 1.12, P=0.004) were negatively correlated with overall survival. Positive/close (<1 mm) margin status (HR 4.34, P=0.030) predicted worsened local recurrence-free survival.
CONCLUSIONS: MFS exhibit a propensity for local recurrence, which is predicted by resection with positive or close margins. Aggressive surgery combined with radiotherapy may contribute to more effective local control.

Entities:  

Mesh:

Year:  2012        PMID: 22890594      PMCID: PMC3837421          DOI: 10.1245/s10434-012-2572-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  19 in total

1.  Low-grade myxofibrosarcoma: progression in recurrence.

Authors:  M Fukunaga; N Fukunaga
Journal:  Pathol Int       Date:  1997 Feb-Mar       Impact factor: 2.534

2.  Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification.

Authors:  C D Fletcher; P Gustafson; A Rydholm; H Willén; M Akerman
Journal:  J Clin Oncol       Date:  2001-06-15       Impact factor: 44.544

3.  Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma.

Authors:  P W Pisters; L B Harrison; D H Leung; J M Woodruff; E S Casper; M F Brennan
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

4.  Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis.

Authors:  C Merck; L Angervall; L G Kindblom; A Odén
Journal:  Acta Pathol Microbiol Immunol Scand Suppl       Date:  1983

5.  Myxofibrosarcoma. A study of 30 cases.

Authors:  L Angervall; L G Kindblom; C Merck
Journal:  Acta Pathol Microbiol Scand A       Date:  1977-03

6.  Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma.

Authors:  Karl E Haglund; Chandrajit P Raut; Alessandra F Nascimento; Qian Wang; Suzanne George; Elizabeth H Baldini
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-15       Impact factor: 7.038

7.  The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy.

Authors:  S A Rosenberg; J Tepper; E Glatstein; J Costa; A Baker; M Brennan; E V DeMoss; C Seipp; W F Sindelar; P Sugarbaker; R Wesley
Journal:  Ann Surg       Date:  1982-09       Impact factor: 12.969

8.  Myxoid variant of malignant fibrous histiocytoma.

Authors:  S W Weiss; F M Enzinger
Journal:  Cancer       Date:  1977-04       Impact factor: 6.860

9.  Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems.

Authors:  Hsuan-Ying Huang; Priti Lal; Jing Qin; Murray F Brennan; Cristina R Antonescu
Journal:  Hum Pathol       Date:  2004-05       Impact factor: 3.466

10.  Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant.

Authors:  T Mentzel; E Calonje; C Wadden; R S Camplejohn; A Beham; M A Smith; C D Fletcher
Journal:  Am J Surg Pathol       Date:  1996-04       Impact factor: 6.394

View more
  34 in total

1.  Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.

Authors:  Ann Y Lee; Narasimhan P Agaram; Li-Xuan Qin; Deborah Kuk; Christina Curtin; Murray F Brennan; Samuel Singer
Journal:  Ann Surg Oncol       Date:  2016-01-12       Impact factor: 5.344

Review 2.  Differential diagnosis of T2 hypointense masses in musculoskeletal MRI.

Authors:  Dara Finkelstein; Gregory Foremny; Adam Singer; Paul Clifford; Juan Pretell-Mazzini; Darcy A Kerr; Ty K Subhawong
Journal:  Skeletal Radiol       Date:  2021-03-02       Impact factor: 2.199

3.  Local Recurrence of Soft Tissue Sarcoma Revisited: Is there a Role for "Selective" Radiation?

Authors:  Nathan E Saxby; Qiang An; Benjamin J Miller
Journal:  Iowa Orthop J       Date:  2022-06

4.  A Unique Presentation of Pulmonary Vein Thrombosis in a Patient With Rapidly Progressive Metastatic Pelvic Myxofibrosarcoma.

Authors:  Lex P Leonhardt; Aamir Pervez; Wesley Tang; Marvin Amen
Journal:  Cureus       Date:  2022-09-07

5.  Molecular and clinicopathological analysis revealed an immuno-checkpoint inhibitor as a potential therapeutic target in a subset of high-grade myxofibrosarcoma.

Authors:  Atsushi Yamashita; Yoshiyuki Suehara; Takuo Hayashi; Tatsuya Takagi; Daisuke Kubota; Keita Sasa; Nobuhiko Hasegawa; Muneaki Ishijima; Takashi Yao; Tsuyoshi Saito
Journal:  Virchows Arch       Date:  2022-06-15       Impact factor: 4.535

6.  Limb-sparing surgery with latissimus dorsi flap reconstruction in extremity soft tissue sarcoma: Case series.

Authors:  Erwin Danil Yulian; Hana Qonita; Evelina Kodrat; Kevin Varian Marcevianto
Journal:  Int J Surg Case Rep       Date:  2022-06-24

7.  Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.

Authors:  Tomoyo Okada; Ann Y Lee; Li-Xuan Qin; Narasimhan Agaram; Takahiro Mimae; Yawei Shen; Rachael O'Connor; Miguel A López-Lago; Amanda Craig; Martin L Miller; Phaedra Agius; Evan Molinelli; Nicholas D Socci; Aimee M Crago; Fumi Shima; Chris Sander; Samuel Singer
Journal:  Cancer Discov       Date:  2016-08-30       Impact factor: 39.397

8.  Myxofibrosarcoma of the scalp with difficult preoperative diagnosis: A case report and review of the literature.

Authors:  Xiao-Ting Ke; Xiong-Feng Yu; Ji-Yang Liu; Fang Huang; Mei-Gui Chen; Qing-Quan Lai
Journal:  World J Clin Cases       Date:  2020-06-06       Impact factor: 1.337

9.  Prognostic Impact of CD44 Expression in Patients With Myxofibrosarcoma.

Authors:  Hiroyuki Tsuchie; Makoto Emori; Naohisa Miyakoshi; Hiroyuki Nagasawa; Kyoji Okada; Hiroshi Nanjyo; Yasutaka Murahashi; Emi Mizushima; Junya Shimizu; Toshihiko Yamashita; Yoichi Shimada
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

10.  Myxofibrosarcoma with associated Mycobacterium infection.

Authors:  Sean Chen; Peter Mattei; Jens U Berli; Jaimie Shores
Journal:  Eplasty       Date:  2014-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.